Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021

A Satellite Symposium of Novartis Pharma was held on January 29th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. It was dedicated to the diagnostics and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with a PIK3CA mutation u...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Editorial Board
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	hormone-receptor-positive her2-negative advanced breast cancer pik3ca mutation piqray alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a6d2aec1f0f646d38f5a81aae27f6f67
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a6d2aec1f0f646d38f5a81aae27f6f67
record_format	dspace
spelling	oai:doaj.org-article:a6d2aec1f0f646d38f5a81aae27f6f672021-11-30T16:55:00ZPiqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 20211815-14341815-144210.26442/18151434.2021.1.200752https://doaj.org/article/a6d2aec1f0f646d38f5a81aae27f6f672021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70297/51229https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442A Satellite Symposium of Novartis Pharma was held on January 29th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. It was dedicated to the diagnostics and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with a PIK3CA mutation using target drug Piqray (alpelisib). Experts-oncologists discussed the diagnostics of the PIK3CA mutation, data from clinical studies of alpelisib, characteristics of patients who may benefit from the alpelisib, prevention and control of adverse events that may develop during therapy with alpelisib. For planning anticancer therapy using alpelisib in combination with fulvestrant, all patients with HR+ HER2- aBC should be tested for PIK3CA mutation at the first signs of a metastatic process. Data from clinical trials demonstrate that this combination provides approximately 2-fold increase in median progression free survival compared to a placebo + fulvestrant combination. Alpelisib can be prescribed to patients with HR+ HER2- aBC with a PIK3CA mutation after progression on endocrine therapy, in a combined mode. The main adverse events hyperglycemia and rash are associated with the mechanism of alpelisib action, and are predictable and manageable.Editorial BoardIP Habib O.N.articlehormone-receptor-positive her2-negative advanced breast cancerpik3ca mutationpiqrayalpelisibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 48-52 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	hormone-receptor-positive her2-negative advanced breast cancer pik3ca mutation piqray alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hormone-receptor-positive her2-negative advanced breast cancer pik3ca mutation piqray alpelisib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Editorial Board Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
description	A Satellite Symposium of Novartis Pharma was held on January 29th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. It was dedicated to the diagnostics and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with a PIK3CA mutation using target drug Piqray (alpelisib). Experts-oncologists discussed the diagnostics of the PIK3CA mutation, data from clinical studies of alpelisib, characteristics of patients who may benefit from the alpelisib, prevention and control of adverse events that may develop during therapy with alpelisib. For planning anticancer therapy using alpelisib in combination with fulvestrant, all patients with HR+ HER2- aBC should be tested for PIK3CA mutation at the first signs of a metastatic process. Data from clinical trials demonstrate that this combination provides approximately 2-fold increase in median progression free survival compared to a placebo + fulvestrant combination. Alpelisib can be prescribed to patients with HR+ HER2- aBC with a PIK3CA mutation after progression on endocrine therapy, in a combined mode. The main adverse events hyperglycemia and rash are associated with the mechanism of alpelisib action, and are predictable and manageable.
format	article
author	Editorial Board
author_facet	Editorial Board
author_sort	Editorial Board
title	Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
title_short	Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
title_full	Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
title_fullStr	Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
title_full_unstemmed	Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
title_sort	piqray – basic questions at the start: whom to test? whom to treat? how to treat? event review of the satellite symposium. russco big conference «breast cancer» (online). january 29th, 2021
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/a6d2aec1f0f646d38f5a81aae27f6f67
work_keys_str_mv	AT editorialboard piqraybasicquestionsatthestartwhomtotestwhomtotreathowtotreateventreviewofthesatellitesymposiumrusscobigconferencebreastcanceronlinejanuary29th2021
_version_	1718406463659966464

Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021

Ejemplares similares